Metabolica Sp. z o.o.
- Address
- ul. Najświętszej Marii Panny 9B, 33-100 Tarnow, Poland
Cardiovascular Diseases
The site focuses on Cardiovascular Diseases, addressing conditions such as Atherosclerotic Cardiovascular Disease. Ongoing research evaluates the safety of emerging agents like olezarsen and investigates how AZD0780 may lower the incidence of MACE-PLUS events in high‑risk patients.
- Safety profiling of novel lipid‑targeting compounds
- Assessment of composite cardiovascular outcome measures
- Strategies for reducing major adverse cardiac events
Metabolica Sp. z o.o. in Tarnow, Poland, conducts these focused studies with a dedicated investigator team, contributing valuable data to cardiovascular care.
Nutritional and Metabolic Diseases
Research at the centre also covers nutritional and metabolic diseases, with a particular emphasis on Severe Hypertriglyceridemia. Clinical work examines the tolerability and effectiveness of olezarsen administered subcutaneously to manage extreme triglyceride levels.
- Evaluation of triglyceride‑lowering therapies
- Exploration of subcutaneous antisense delivery methods
- Patient-reported outcomes in metabolic disorder trials
The facility’s targeted approach aims to improve metabolic health outcomes while maintaining rigorous safety standards for participants.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1AstraZeneca AB1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Metabolica Sp. z o.o.
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| An Open-Label Extension Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Patients with Severe Hypertriglyceridemia (SHTG) | Ionis Pharmaceuticals Inc. | Phase III | Not Recruiting | Jul 2023 | — |
IMP list
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Isis 678354 Sodium Salt | 1 | Unknown | 2023-07-12 | 2023-07-12 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.